Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function

Schizophrenia is a severe psychiatric disorder with a world-wide prevalence of 1%. The pathophysiology of the illness is not understood, but is thought to have a strong genetic component with some environmental influences on aetiology. To gain further insight into disease mechanism, we used microarray technology to determine the expression of over 30 000 mRNA transcripts in post-mortem tissue from a brain region associated with the pathophysiology of the disease (Brodmann area 10: anterior prefrontal cortex) in 28 schizophrenic and 23 control patients. We then compared our study (Charing Cross Hospital prospective collection) with that of an independent prefrontal cortex dataset from the Harvard Brain Bank. We report the first direct comparison between two independent studies. A total of 51 gene expression changes have been identified that are common between the schizophrenia cohorts, and 49 show the same direction of disease-associated regulation. In particular, changes were observed in gene sets associated with synaptic vesicle recycling, transmitter release and cytoskeletal dynamics. This strongly suggests multiple, small but synergistic changes in gene expression that affect nerve terminal function.

[1]  M. Goedert,et al.  Synaptotagmin V: a novel synaptotagmin isoform expressed in rat brain , 1995, FEBS letters.

[2]  R. Palmiter,et al.  Ultrastructural localization of zinc transporter-3 (ZnT-3) to synaptic vesicle membranes within mossy fiber boutons in the hippocampus of mouse and monkey. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Y. Takai,et al.  Role of the Doc2α–Munc13–1 interaction in the neurotransmitter release process , 1998 .

[4]  T. Sasaki,et al.  Role of the Doc2 alpha-Munc13-1 interaction in the neurotransmitter release process. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Palmiter,et al.  Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Murray,et al.  Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. , 1999, Archives of general psychiatry.

[7]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[8]  S. Bustin.  Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.

[9]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Palmiter,et al.  Removing zinc from synaptic vesicles does not impair spatial learning, memory, or sensorimotor functions in the mouse , 2001, Brain Research.

[11]  Janice A. Nagy,et al.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor , 2001, Nature Medicine.

[12]  A. Cools,et al.  Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  N. Cairns,et al.  The quantification of gene expression in an animal model of brain ischaemia using TaqMan real-time RT-PCR. , 2002, Brain research. Molecular brain research.

[14]  Daniel R Weinberger,et al.  Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study , 2002, Schizophrenia Research.

[15]  J. Pierri,et al.  Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.

[16]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[17]  Peter B. Jones,et al.  Oligodendrocyte dysfunction in schizophrenia and bipolar disorder , 2003, The Lancet.

[18]  R. Yolken,et al.  Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress , 2004, Molecular Psychiatry.

[19]  Seon-Young Kim,et al.  PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinform..

[20]  F. Middleton,et al.  Gene Expression Profiling with DNA Microarrays: Advancing Our Understanding of Psychiatric Disorders , 2002, Neurochemical Research.

[21]  T. Sudhof,et al.  The synaptic vesicle cycle. , 2004, Annual review of neuroscience.

[22]  Huda Akil,et al.  Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain , 2004, Biological Psychiatry.

[23]  Ryszard Maleszka,et al.  Microarray reality checks in the context of a complex disease , 2004, Nature Biotechnology.

[24]  Eileen Luders,et al.  Gender differences in cortical complexity , 2004, Nature Neuroscience.

[25]  Raquel E Gur,et al.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. , 2004, The Journal of clinical investigation.

[26]  C. Konradi,et al.  Gene expression microarray studies in polygenic psychiatric disorders: Applications and data analysis , 2005, Brain Research Reviews.

[27]  A. Bush,et al.  The neurobiology of zinc in health and disease , 2005, Nature Reviews Neuroscience.

[28]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[29]  Jonathan D. Cohen,et al.  Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. , 2005, The American journal of psychiatry.

[30]  R Freedman,et al.  Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. , 2005, Brain research. Molecular brain research.

[31]  Paul J. Harrison,et al.  Schizophrenia: a genetic disorder of the synapse? , 2005, BMJ : British Medical Journal.

[32]  Jacques Corbeil,et al.  Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Kalman,et al.  Vglut1 and ZnT3 co-targeting mechanisms regulate vesicular zinc stores in PC12 cells , 2005, Journal of Cell Science.

[34]  P. Greengard,et al.  Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology , 2006, Nature.

[35]  P. Lory,et al.  Voltage-gated calcium channels in genetic diseases. , 2006, Biochimica et biophysica acta.

[36]  J. Kleinman,et al.  Critical Factors in Gene Expression in Postmortem Human Brain: Focus on Studies in Schizophrenia , 2006, Biological Psychiatry.

[37]  Hongyue Dai,et al.  Rosetta error model for gene expression analysis , 2006, Bioinform..

[38]  R. Myers,et al.  Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders , 2006, Molecular Psychiatry.

[39]  Sarah A. J. Reading,et al.  Neurobiology of Schizophrenia , 2006, Neuron.

[40]  Gustavo Turecki,et al.  Genome wide gene expression studies in mood disorders. , 2006, Omics : a journal of integrative biology.

[41]  James M. Stone,et al.  Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review , 2007, Journal of psychopharmacology.

[42]  Pat Levitt,et al.  Molecular Evidence for Increased Expression of Genes Related to Immune and Chaperone Function in the Prefrontal Cortex in Schizophrenia , 2007, Biological Psychiatry.

[43]  K Mizuguchi,et al.  Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia , 2007, Molecular Psychiatry.

[44]  Johan Kreuger,et al.  Inflammation-related genes up-regulated in schizophrenia brains , 2007 .

[45]  Vahram Haroutunian,et al.  Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia , 2007, Schizophrenia Research.

[46]  M. Cobb,et al.  WNK1 Is a Novel Regulator of Munc18c-Syntaxin 4 Complex Formation in Soluble NSF Attachment Protein Receptor (SNARE)-mediated Vesicle Exocytosis* , 2007, Journal of Biological Chemistry.

[47]  Richard D Emes,et al.  Evolutionary expansion and anatomical specialization of synapse proteome complexity , 2008, Nature Neuroscience.

[48]  Y. Goda,et al.  Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy , 2008, Nature Reviews Neuroscience.

[49]  Jong H. Yoon,et al.  Association of dorsolateral prefrontal cortex dysfunction with disrupted coordinated brain activity in schizophrenia: relationship with impaired cognition, behavioral disorganization, and global function. , 2008, The American journal of psychiatry.

[50]  R. Vakkalanka,et al.  Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia , 2008, Schizophrenia Research.

[51]  J. Rizo,et al.  Synaptic vesicle fusion , 2008, Nature Structural &Molecular Biology.

[52]  Y. Goda,et al.  Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy , 2008, Nature Reviews Neuroscience.

[53]  Y. Barral,et al.  The septin family of GTPases: architecture and dynamics , 2008, Nature Reviews Molecular Cell Biology.

[54]  P. Sullivan.  Schizophrenia genetics: the search for a hard lead , 2008, Current opinion in psychiatry.

[55]  K. Kendler,et al.  The dystrobrevin-binding protein 1 gene: features and networks , 2009, Molecular Psychiatry.

[56]  B. Barbour,et al.  Zinc at glutamatergic synapses , 2009, Neuroscience.